{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:11:55Z","timestamp":1793394715538,"version":"4.5.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s00228-023-03579-0","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T06:01:25Z","timestamp":1699336885000},"page":"11-37","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Factors influencing methotrexate pharmacokinetics highlight the need for individualized dose adjustment: a systematic review"],"prefix":"10.1007","volume":"80","author":[{"given":"Yunyun","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuebin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7999-7162","authenticated-orcid":false,"given":"Zheng","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,7]]},"reference":[{"key":"3579_CR1","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1039\/c7an00367f","volume":"142","author":"N Guichard","year":"2017","unstructured":"Guichard N, Guillarme D, Bonnabry P, Fleury-Souverain S (2017) Antineoplastic drugs and their analysis: a state of the art review. Analyst 142:2273\u20132321. https:\/\/doi.org\/10.1039\/c7an00367f","journal-title":"Analyst"},{"key":"3579_CR2","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1002\/art.1780391203","volume":"39","author":"BN Cronstein","year":"1996","unstructured":"Cronstein BN (1996) Molecular therapeutics. methotrexate and its mechanism of action. Arthritis Rheum 39:1951\u20131960. https:\/\/doi.org\/10.1002\/art.1780391203","journal-title":"Arthritis Rheum"},{"key":"3579_CR3","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.3390\/cancers13112837","volume":"13","author":"ZL Taylor","year":"2021","unstructured":"Taylor ZL, Vang J, Lopez-Lopez E, Oosterom N, Mikkelsen T, Ramsey LB (2021) Systematic review of pharmacogenetic factors that influence high-dose methotrexate pharmacokinetics in pediatric malignancies. Cancers (Basel) 13:2837. https:\/\/doi.org\/10.3390\/cancers13112837","journal-title":"Cancers (Basel)"},{"key":"3579_CR4","unstructured":"Methotrexate (Jiangsu Hengrui Pharmaceutical Co., LTD): drug information"},{"key":"3579_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/art.1780310203","volume":"31","author":"ME Weinblatt","year":"1988","unstructured":"Weinblatt ME, Trentham DE, Fraser PA, Holdsworth DE, Falchuk KR, Weissman BN, Coblyn JS (1988) Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum 31:167\u2013175. https:\/\/doi.org\/10.1002\/art.1780310203","journal-title":"Arthritis Rheum"},{"key":"3579_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard.62.1.15","volume":"62","author":"C Morgan","year":"2003","unstructured":"Morgan C, Lunt M, Brightwell H, Bradburn P, Fallow W, Lay M, Silman A, Bruce IN (2003) Contribution of patient related differences to multidrug resistance in rheumatoid arthritis. Ann Rheum Dis 62:15\u201319. https:\/\/doi.org\/10.1136\/ard.62.1.15","journal-title":"Ann Rheum Dis"},{"key":"3579_CR7","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1200\/JCO.2006.06.9591","volume":"24","author":"MG Kris","year":"2006","unstructured":"American Society of Clinical Oncology, Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24:2932\u20132947. https:\/\/doi.org\/10.1200\/JCO.2006.06.9591","journal-title":"J Clin Oncol"},{"key":"3579_CR8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1634\/theoncologist.2017-0243","volume":"23","author":"LB Ramsey","year":"2018","unstructured":"Ramsey LB, Balis FM, MM, Schmiegelow K, Pauley JL, Bleyer A, Widemann BC, Askenazi D, Bergeron S, Shirali A, Schwartz S, Vinks AA, Heldrup J, (2018) Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance. Oncologist 23:52\u201361. https:\/\/doi.org\/10.1634\/theoncologist.2017-0243","journal-title":"Oncologist"},{"key":"3579_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003088-197803010-00001","volume":"3","author":"DD Shen","year":"1978","unstructured":"Shen DD, Azarnoff DL (1978) Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet 3:1\u201313. https:\/\/doi.org\/10.2165\/00003088-197803010-00001","journal-title":"Clin Pharmacokinet"},{"key":"3579_CR10","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1016\/j.ejca.2014.04.014","volume":"50","author":"A Paci","year":"2014","unstructured":"Paci A, Veal G, Bardin C, Lev\u00eaque D, Widmer N, Beijnen J, Astier A, Chatelut E (2014) Review of therapeutic drug monitoring of anticancer drugs part 1 \u2013 cytotoxics. Eur J Cancer 50:2010\u20132019. https:\/\/doi.org\/10.1016\/j.ejca.2014.04.014","journal-title":"Eur J Cancer"},{"key":"3579_CR11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/j.1365-2125.2011.04054.x","volume":"73","author":"L Holmboe","year":"2012","unstructured":"Holmboe L, Andersen AM, M\u00f8rkrid L, Sl\u00f8rdal L, Hall KS (2012) High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients. Br J Clin Pharmacol 73:106\u2013114. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.04054.x","journal-title":"Br J Clin Pharmacol"},{"key":"3579_CR12","first-page":"164","volume":"33","author":"C Sabot","year":"1995","unstructured":"Sabot C, Debord J, Roullet B, Marquet P, Merle L, Lachatre G (1995) Comparison of 2- and 3-compartment models for the Bayesian estimation of methotrexate pharmacokinetics. Int J Clin Pharmacol Ther 33:164\u2013169","journal-title":"Int J Clin Pharmacol Ther"},{"key":"3579_CR13","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/0010-4809(72)90051-1","volume":"5","author":"LB Sheiner","year":"1972","unstructured":"Sheiner LB, Rosenberg B, Melmon KL (1972) Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res 5:411\u2013459. https:\/\/doi.org\/10.1016\/0010-4809(72)90051-1","journal-title":"Comput Biomed Res"},{"key":"3579_CR14","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00228-020-02840-0","volume":"76","author":"X Lu","year":"2020","unstructured":"Lu X, Xu G, Chen L, Fan J, Li M, Zhu L (2020) Assessment of micafungin loading dosage regimens against Candida spp. in ICU patients by Monte Carlo simulations. Eur J Clin Pharmacol 76:695\u2013702. https:\/\/doi.org\/10.1007\/s00228-020-02840-0","journal-title":"Eur J Clin Pharmacol"},{"key":"3579_CR15","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.1182\/blood-2007-09-112920","volume":"111","author":"M\u00f6ricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, D\u00f6rdelmann M, L\u00f6ning L, Beier R, Ludwig WD, Ratei R, Harbott J, Boos J, Mann G, Niggli F, Feldges A, Henze G, Welte K, Beck JD, Klingebiel T, Niemeyer C, Zintl F, Bode U, Urban C, Wehinger H, Niethammer D, Riehm H, Schrappe M, German-Austrian-Swiss ALL-BFM Study Group","year":"2008","unstructured":"M\u00f6ricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, D\u00f6rdelmann M, L\u00f6ning L, Beier R, Ludwig WD, Ratei R, Harbott J, Boos J, Mann G, Niggli F, Feldges A, Henze G, Welte K, Beck JD, Klingebiel T, Niemeyer C, Zintl F, Bode U, Urban C, Wehinger H, Niethammer D, Riehm H, Schrappe M, German-Austrian-Swiss ALL-BFM Study Group (2008) Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 111:4477\u20134489. https:\/\/doi.org\/10.1182\/blood-2007-09-112920","journal-title":"Blood"},{"key":"3579_CR16","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1055\/s-2008-1046608","volume":"206","author":"A Reiter","year":"1994","unstructured":"Reiter A, Tiemann M, Ludwig WD, Wacker HH, Yakisan E, Schrappe M, Henzler D, Sykora KW, Brandt A, Odenwald E (1994) NHL-BFM 90 therapy study in treatment of malignant non-Hodgkin\u2019s lymphomas in children and adolescents. Part 1: classification and allocation to strategic therapy groups. BIF study group Klin P\u00e4diatr 206:222\u2013233. https:\/\/doi.org\/10.1055\/s-2008-1046608","journal-title":"BIF study group Klin P\u00e4diatr"},{"key":"3579_CR17","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1056\/NEJM199504063321401","volume":"332","author":"G Bonadonna","year":"1995","unstructured":"Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 332:901\u2013906. https:\/\/doi.org\/10.1056\/NEJM199504063321401","journal-title":"N Engl J Med"},{"key":"3579_CR18","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1056\/NEJM199310213291703","volume":"329","author":"NJ Chao","year":"1993","unstructured":"Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD, Nademanee AP, Negrin RS, O\u2019Donnell MR, Parker PM, Smith EP, Snyder DS, Stein AS, Wong RM, Blume KG, Forman SJ (1993) Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 329:1225\u20131230. https:\/\/doi.org\/10.1056\/NEJM199310213291703","journal-title":"N Engl J Med"},{"key":"3579_CR19","doi-asserted-by":"publisher","first-page":"358","DOI":"10.7326\/0003-4819-107-2-358","volume":"107","author":"P Tugwell","year":"1987","unstructured":"Tugwell P, Bennett K, Gent M (1987) Methotrexate in rheumatoid arthritis. Indications, contraindications, efficacy, and safety. Ann Intern Med 107:358\u2013366. https:\/\/doi.org\/10.7326\/0003-4819-107-2-358","journal-title":"Ann Intern Med"},{"key":"3579_CR20","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1007\/s10157-011-0452-y","volume":"15","author":"O Uemura","year":"2011","unstructured":"Uemura O, Honda M, Matsuyama T, Ishikura K, Hataya H, Yata N, Nagai T, Ikezumi Y, Fujita N, Ito S, Iijima K, Kitagawa T (2011) Age, gender, and body length effects on reference serum creatinine levels determined by an enzymatic method in Japanese children: a multicenter study. Clin Exp Nephrol 15:694\u2013699. https:\/\/doi.org\/10.1007\/s10157-011-0452-y","journal-title":"Clin Exp Nephrol"},{"key":"3579_CR21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31\u201341. https:\/\/doi.org\/10.1159\/000180580","journal-title":"Nephron"},{"key":"3579_CR22","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1177\/00220345010800060701","volume":"80","author":"DR Burns","year":"2001","unstructured":"Burns DR, Elswick RK (2001) Equivalence testing with dental clinical trials. J Dent Res 80:1513\u20131517. https:\/\/doi.org\/10.1177\/00220345010800060701","journal-title":"J Dent Res"},{"key":"3579_CR23","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00280-015-2699-6","volume":"75","author":"KD Wright","year":"2015","unstructured":"Wright KD, Stewart CF (2015) Response to: comment on \u2018Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections.\u2019 Cancer Chemother Pharmacol 75:877\u2013878. https:\/\/doi.org\/10.1007\/s00280-015-2699-6","journal-title":"Cancer Chemother Pharmacol"},{"key":"3579_CR24","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s40262-018-00734-0","volume":"58","author":"RJ Beechinor","year":"2019","unstructured":"Beechinor RJ, Thompson PA, Hwang MF, Vargo RC, Bomgaars LR, Gerhart JG, Dreyer ZE, Gonzalez D (2019) The population pharmacokinetics of high-dose methotrexate in infants with acute lymphoblastic leukemia highlight the need for bedside individualized dose adjustment: a report from the Children\u2019s Oncology Group. Clin Pharmacokinet 58:899\u2013910. https:\/\/doi.org\/10.1007\/s40262-018-00734-0","journal-title":"Clin Pharmacokinet"},{"key":"3579_CR25","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/bcp.14160","volume":"86","author":"JC Panetta","year":"2020","unstructured":"Panetta JC, Roberts JK, Huang J, Lin T, Daryani VM, Harstead KE, Patel YT, Onar-Thomas A, Campagne O, Ward DA, Broniscer A, Robinson G, Gajjar A, Stewart CF (2020) Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumours. Br J Clin Pharmacol 86:362\u2013371. https:\/\/doi.org\/10.1111\/bcp.14160","journal-title":"Br J Clin Pharmacol"},{"key":"3579_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/bdd.2221","volume":"41","author":"ZY Shi","year":"2020","unstructured":"Shi ZY, Liu YO, Gu HY, Xu XQ, Yan C, Yang XY, Yan D (2020) Population pharmacokinetics of high-dose methotrexate in Chinese pediatric patients with medulloblastoma. Biopharm Drug Dispos 41:101\u2013110. https:\/\/doi.org\/10.1002\/bdd.2221","journal-title":"Biopharm Drug Dispos"},{"key":"3579_CR27","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/s00280-006-0202-0","volume":"58","author":"DW Faltaos","year":"2006","unstructured":"Faltaos DW, Hulot JS, Urien S, Morel V, Kaloshi G, Fernandez C, Xuan K, Leblond V, Lechat P (2006) Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy. Cancer Chemother Pharmacol 58:626\u2013633. https:\/\/doi.org\/10.1007\/s00280-006-0202-0","journal-title":"Cancer Chemother Pharmacol"},{"key":"3579_CR28","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/j.1365-2710.2008.00966.x","volume":"33","author":"K Fukuhara","year":"2008","unstructured":"Fukuhara K, Ikawa K, Morikawa N, Kumagai K (2008) Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data. J Clin Pharm Ther 33:677\u2013684. https:\/\/doi.org\/10.1111\/j.1365-2710.2008.00966.x","journal-title":"J Clin Pharm Ther"},{"key":"3579_CR29","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/bdd.678","volume":"30","author":"Y Min","year":"2009","unstructured":"Min Y, Qiang F, Peng L, Zhu Z (2009) High dose methotrexate population pharmacokinetics and Bayesian estimation in patients with lymphoid malignancy. Biopharm Drug Dispos 30:437\u2013447. https:\/\/doi.org\/10.1002\/bdd.678","journal-title":"Biopharm Drug Dispos"},{"key":"3579_CR30","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/tpj.2012.37","volume":"J13","author":"N Simon","year":"2013","unstructured":"Simon N, Marsot A, Villard E, Choquet S, Hoang-Xuan K, Zahr N, Lechat P, Leblond V, Hulot JS (2013) Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy. Pharmacogenom J13:507\u2013513. https:\/\/doi.org\/10.1038\/tpj.2012.37","journal-title":"Pharmacogenom"},{"key":"3579_CR31","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/bcp.12326","volume":"78","author":"I Benz-de Bretagne","year":"2014","unstructured":"Benz-de Bretagne I, Zahr N, Le Gouge A, Hulot JS, Houillier C, Hoang-Xuan K, Gyan E, Lissandre S, Choquet S, Le Guellec C (2014) Urinary coproporphyrin I\/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance. Br J Clin Pharmacol 78:329\u2013342. https:\/\/doi.org\/10.1111\/bcp.12326","journal-title":"Br J Clin Pharmacol"},{"key":"3579_CR32","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1248\/bpb.b13-00672","volume":"37","author":"M Watanabe","year":"2014","unstructured":"Watanabe M, Fukuoka N, Takeuchi T, Yamaguchi K, Motoki T, Tanaka H, Kosaka S, Houchi H (2014) Developing population pharmacokinetic parameters for high-dose methotrexate therapy: implication of correlations among developed parameters for individual parameter estimation using the Bayesian least-squares method. Biol Pharm Bull 37:916\u2013921. https:\/\/doi.org\/10.1248\/bpb.b13-00672","journal-title":"Biol Pharm Bull"},{"key":"3579_CR33","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s13318-016-0338-1","volume":"42","author":"A Nader","year":"2017","unstructured":"Nader A, Zahran N, Alshammaa A, Altaweel H, Kassem N, Wilby KJ (2017) Population pharmacokinetics of intravenous methotrexate in patients with hematological malignancies: utilization of routine clinical monitoring parameters. Eur J Drug Metab Pharmacokinet 42:221\u2013228. https:\/\/doi.org\/10.1007\/s13318-016-0338-1","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"3579_CR34","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/j.xphs.2018.01.004","volume":"107","author":"S Mei","year":"2018","unstructured":"Mei S, Li X, Jiang X, Yu K, Lin S, Zhao Z (2018) Population pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma. J Pharm Sci 107:1454\u20131460. https:\/\/doi.org\/10.1016\/j.xphs.2018.01.004","journal-title":"J Pharm Sci"},{"key":"3579_CR35","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00280-020-04058-4","volume":"85","author":"L Yang","year":"2020","unstructured":"Yang L, Wu H, de Winter BCM, Sheng CC, Qiu HQ, Cheng Y, Chen J, Zhao QL, Huang J, Jiao Z, Xie RX (2020) Pharmacokinetics and pharmacogenetics of high-dose methotrexate in Chinese adult patients with non-Hodgkin lymphoma: a population analysis. Cancer Chemother Pharmacol 85:881\u2013897. https:\/\/doi.org\/10.1007\/s00280-020-04058-4","journal-title":"Cancer Chemother Pharmacol"},{"key":"3579_CR36","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/phar.2379","volume":"40","author":"MP Pai","year":"2020","unstructured":"Pai MP, Debacker KC, Derstine B, Sullivan J, Su GL, Wang SC (2020) Comparison of body size, morphomics, and kidney function as covariates of high-dose methotrexate clearance in obese adults with primary central nervous system lymphoma. Pharmacotherapy 40:308\u2013319. https:\/\/doi.org\/10.1002\/phar.2379","journal-title":"Pharmacotherapy"},{"key":"3579_CR37","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1097\/FTD.0000000000000813","volume":"43","author":"F Gallais","year":"2021","unstructured":"Gallais F, Oberic L, Faguer S, Tavitian S, Lafont T, Marsili S, Brice A, Chatelut E, Puisset F (2021) Body surface area dosing of high-dose methotrexate should be reconsidered, particularly in overweight, adult patients. Ther Drug Monit 43:408\u2013415. https:\/\/doi.org\/10.1097\/FTD.0000000000000813","journal-title":"Ther Drug Monit"},{"key":"3579_CR38","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1186\/s12885-021-08443-x","volume":"21","author":"U Arshad","year":"2021","unstructured":"Arshad U, Taubert M, Seeger-Nukpezah T, Ullah S, Spindeldreier KC, Jaehde U, Hallek M, Fuhr U, Vehreschild JJ, Jakob C (2021) Evaluation of body-surface-area adjusted dosing of high-dose methotrexate by population pharmacokinetics in a large cohort of cancer patients. BMC Cancer 21:719. https:\/\/doi.org\/10.1186\/s12885-021-08443-x","journal-title":"BMC Cancer"},{"key":"3579_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.883","volume":"9","author":"T Isono","year":"2021","unstructured":"Isono T, Hira D, Morikochi A, Fukami T, Ueshima S, Nozaki K, Terada T, Morita SY (2021) Urine volume to hydration volume ratio is associated with pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma. Pharmacol Res Perspect 9:e00883. https:\/\/doi.org\/10.1002\/prp2.883","journal-title":"Pharmacol Res Perspect"},{"key":"3579_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.817673","volume":"13","author":"J Mao","year":"2022","unstructured":"Mao J, Li Q, Li P, Qin W, Chen B, Zhong M (2022) Evaluation and application of population pharmacokinetic models for identifying delayed methotrexate elimination in patients with primary central nervous system lymphoma. Front Pharmacol 13:817673. https:\/\/doi.org\/10.3389\/fphar.2022.817673","journal-title":"Front Pharmacol"},{"key":"3579_CR41","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.2165\/00003088-200645120-00007","volume":"45","author":"D Aumente","year":"2006","unstructured":"Aumente D, Buelga DS, Lukas JC, Gomez P, Torres A, Garc\u00eda MJ (2006) Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. Clin Pharmacokinet 45:1227\u20131238. https:\/\/doi.org\/10.2165\/00003088-200645120-00007","journal-title":"Clin Pharmacokinet"},{"key":"3579_CR42","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/FTD.0b013e3181945624","volume":"31","author":"H Colom","year":"2009","unstructured":"Colom H, Farr\u00e9 R, Soy D, Peraire C, Cendros JM, Pardo N, Torrent M, Domenech J, Mangues MA (2009) Population pharmacokinetics of high-dose methotrexate after intravenous administration in pediatric patients with osteosarcoma. Ther Drug Monit 31:76\u201385. https:\/\/doi.org\/10.1097\/FTD.0b013e3181945624","journal-title":"Ther Drug Monit"},{"key":"3579_CR43","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s00228-011-1046-z","volume":"67","author":"B Faganel Kotnik","year":"2011","unstructured":"Faganel Kotnik B, Grabnar I, Bohanec Grabar P, Dol\u017ean V, Jazbec J (2011) Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma. Eur J Clin Pharmacol 67:993\u20131006. https:\/\/doi.org\/10.1007\/s00228-011-1046-z","journal-title":"Eur J Clin Pharmacol"},{"key":"3579_CR44","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4236\/pp.2013.42020","volume":"4","author":"ESE Desoky","year":"2013","unstructured":"Desoky ESE, Ghazal MH, Singh RP, Abdelhamid ON, Derendorf H (2013) Population pharmacokinetics of methotrexate in Egyptian children with lymphoblastic leukemia. Pharmacol Pharm 4:139\u2013145. https:\/\/doi.org\/10.4236\/pp.2013.42020","journal-title":"Pharmacol Pharm"},{"key":"3579_CR45","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/jcph.1349","volume":"59","author":"KH Hui","year":"2019","unstructured":"Hui KH, Chu HM, Fong PS, Cheng WTF, Lam TN (2019) Population pharmacokinetic study and individual dose adjustments of high-dose methotrexate in Chinese pediatric patients with acute lymphoblastic leukemia or osteosarcoma. J Clin Pharmacol 59:566\u2013577. https:\/\/doi.org\/10.1002\/jcph.1349","journal-title":"J Clin Pharmacol"},{"key":"3579_CR46","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1002\/jcph.1252","volume":"58","author":"Lui G, Treluyer JM, Fresneau B, Piperno-Neumann S, Gaspar N, Corradini N, Gentet JC, Marec Berard PM, Laurence V, Schneider P, Entz-Werle N, Pacquement H, Millot F, Taque S, Freycon C, Lervat C, Le Deley MC, Mahier Ait Oukhatar C, Brugieres L, Le Teuff G, Bouazza N, Sarcoma Group of UNICANCER","year":"2018","unstructured":"Lui G, Treluyer JM, Fresneau B, Piperno-Neumann S, Gaspar N, Corradini N, Gentet JC, Marec Berard PM, Laurence V, Schneider P, Entz-Werle N, Pacquement H, Millot F, Taque S, Freycon C, Lervat C, Le Deley MC, Mahier Ait Oukhatar C, Brugieres L, Le Teuff G, Bouazza N, Sarcoma Group of UNICANCER (2018) A pharmacokinetic and pharmacogenetic analysis of osteosarcoma patients treated with high-dose methotrexate: data from the OS2006\/Sarcoma-09 trial. J Clin Pharmacol 58:1541\u20131549. https:\/\/doi.org\/10.1002\/jcph.1252","journal-title":"J Clin Pharmacol"},{"key":"3579_CR47","doi-asserted-by":"publisher","first-page":"402","DOI":"10.5414\/CP203423","volume":"57","author":"YN Zang","year":"2019","unstructured":"Zang YN, Wang SZ, Qin Y, Zhang JR, Zhao LB, Wang XL (2019) Population pharmacokinetic study of delayed methotrexate excretion in children with acute lymphoblastic leukemia. Int J Clin Pharmacol Ther 57:402\u2013407. https:\/\/doi.org\/10.5414\/CP203423","journal-title":"Int J Clin Pharmacol Ther"},{"key":"3579_CR48","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00280-019-03977-1","volume":"85","author":"SE Medellin-Garibay","year":"2020","unstructured":"Medellin-Garibay SE, Hern\u00e1ndez-Villa N, Correa-Gonz\u00e1lez LC, Morales-Barrag\u00e1n MN, Valero-Rivera KP, Res\u00e9ndiz-Galv\u00e1n JE, Ortiz-Zamudio JJ, Mil\u00e1n-Segovia RDC, Romano-Moreno S (2020) Population pharmacokinetics of methotrexate in Mexican pediatric patients with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 85:21\u201331. https:\/\/doi.org\/10.1007\/s00280-019-03977-1","journal-title":"Cancer Chemother Pharmacol"},{"key":"3579_CR49","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/cpt.1957","volume":"108","author":"ZL Taylor","year":"2020","unstructured":"Taylor ZL, Mizuno T, Punt NC, Baskaran B, Navarro Sainz A, Shuman W, Felicelli N, Vinks AA, Heldrup J, Ramsey LB (2020) MTXPK.org: a clinical decision support tool evaluating high-dose methotrexate pharmacokinetics to inform post-infusion care and use of glucarpidase. MTXPK.org. Clin Pharmacol Ther 108:635\u2013643. https:\/\/doi.org\/10.1002\/cpt.1957","journal-title":"Clin Pharmacol Ther"},{"key":"3579_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.701452","volume":"12","author":"X Gao","year":"2021","unstructured":"Gao X, Qian XW, Zhu XH, Yu Y, Miao H, Meng JH, Jiang JY, Wang HS, Zhai XW (2021) Population pharmacokinetics of high-dose methotrexate in Chinese pediatric patients with acute lymphoblastic leukemia. Front Pharmacol 12:701452. https:\/\/doi.org\/10.3389\/fphar.2021.701452","journal-title":"Front Pharmacol"},{"key":"3579_CR51","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1080\/00498254.2022.2069060","volume":"52","author":"M Zhan","year":"2022","unstructured":"Zhan M, Sun Y, Zhou F, Wang H, Chen Z, Yan L, Li X (2022) Population pharmacokinetics of methotrexate in paediatric patients with acute lymphoblastic leukaemia and malignant lymphoma. Xenobiotica 52:265\u2013273. https:\/\/doi.org\/10.1080\/00498254.2022.2069060","journal-title":"Xenobiotica"},{"key":"3579_CR52","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1097\/FTD.0b013e31823615e1","volume":"33","author":"\u00c5M Johansson","year":"2011","unstructured":"Johansson \u00c5M, Hill N, Perisoglou M, Whelan J, Karlsson MO, Standing JF (2011) A population pharmacokinetic\/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma. Ther Drug Monit 33:711\u2013718. https:\/\/doi.org\/10.1097\/FTD.0b013e31823615e1","journal-title":"Ther Drug Monit"},{"key":"3579_CR53","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1365-2125.2011.04084.x","volume":"73","author":"M Joerger","year":"2012","unstructured":"Joerger M, Ferreri AJ, Kr\u00e4henb\u00fchl S, Schellens JH, Cerny T, Zucca E, Huitema ADR (2012) Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate. Br J Clin Pharmacol 73:240\u2013247. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.04084.x","journal-title":"Br J Clin Pharmacol"},{"key":"3579_CR54","doi-asserted-by":"publisher","first-page":"111","DOI":"10.4103\/0366-6999.147829","volume":"128","author":"W Zhang","year":"2015","unstructured":"Zhang W, Zhang Q, Tian X, Zhao H, Lu W, Zhen J, Niu X (2015) Population pharmacokinetics of high-dose methotrexate after intravenous administration in Chinese osteosarcoma patients from a single institution. Chin Med J (Engl) 128:111\u2013118. https:\/\/doi.org\/10.4103\/0366-6999.147829","journal-title":"Chin Med J (Engl)"},{"key":"3579_CR55","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s00280-019-03966-4","volume":"84","author":"S Kawakatsu","year":"2019","unstructured":"Kawakatsu S, Nikanjam M, Lin M, Le S, Saunders I, Kuo DJ, Capparelli EV (2019) Population pharmacokinetic analysis of high-dose methotrexate in pediatric and adult oncology patients. Cancer Chemother Pharmacol 84:1339\u20131348. https:\/\/doi.org\/10.1007\/s00280-019-03966-4","journal-title":"Cancer Chemother Pharmacol"},{"key":"3579_CR56","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/cts.12879","volume":"14","author":"RR Schulte","year":"2021","unstructured":"Schulte RR, Choi L, Utreja N, Van Driest SL, Stein CM, Ho RH (2021) Effect of SLCO1B1 polymorphisms on high-dose methotrexate clearance in children and young adults with leukemia and lymphoblastic lymphoma. Clin Transl Sci 14:343\u2013353. https:\/\/doi.org\/10.1111\/cts.12879","journal-title":"Clin Transl Sci"},{"key":"3579_CR57","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1046\/j.1365-2125.1998.t01-1-00790.x","volume":"46","author":"C Godfrey","year":"1998","unstructured":"Godfrey C, Sweeney K, Miller K, Hamilton R, Kremer J (1998) The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. Br J Clin Pharmacol 46:369\u2013376. https:\/\/doi.org\/10.1046\/j.1365-2125.1998.t01-1-00790.x","journal-title":"Br J Clin Pharmacol"},{"key":"3579_CR58","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/s0959-8049(02)00024-2","volume":"38","author":"MA Batey","year":"2002","unstructured":"Batey MA, Wright JG, Azzabi A, Newell DR, Lind MJ, Calvert AH, Boddy AV (2002) Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Eur J Cancer 38:1081\u20131089. https:\/\/doi.org\/10.1016\/s0959-8049(02)00024-2","journal-title":"Eur J Cancer"},{"key":"3579_CR59","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/j.1365-2710.2007.00859.x","volume":"32","author":"E Yukawa","year":"2007","unstructured":"Yukawa E, Mori S, Ueda K, Nakada Y (2007) Population pharmacokinetic investigation of low-dose methotrexate in rheumatoid arthritics Japanese patients. J Clin Pharm Ther 32:573\u2013578. https:\/\/doi.org\/10.1111\/j.1365-2710.2007.00859.x","journal-title":"J Clin Pharm Ther"},{"key":"3579_CR60","first-page":"403","volume":"11","author":"M Nagulu","year":"2010","unstructured":"Nagulu M, Kiran VU, Nalini Y, Reddy YN, Krishna DR (2010) Population pharmacokinetics of methotrexate in Indian cancer patients. Asian Pac J Cancer Prev 11:403\u2013407","journal-title":"Asian Pac J Cancer Prev"},{"key":"3579_CR61","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1016\/j.clinthera.2012.06.022","volume":"34","author":"IW Kim","year":"2012","unstructured":"Kim IW, Yun HY, Choi B, Han N, Park SY, Lee ES, Oh JM (2012) ABCB1 C3435T genetic polymorphism on population pharmacokinetics of methotrexate after hematopoietic stem cell transplantation in Korean patients: a prospective analysis. Clin Ther 34:1816\u20131826. https:\/\/doi.org\/10.1016\/j.clinthera.2012.06.022","journal-title":"Clin Ther"},{"key":"3579_CR62","doi-asserted-by":"publisher","first-page":"592","DOI":"10.2174\/1389200220666190701094756","volume":"20","author":"Z Wang","year":"2019","unstructured":"Wang Z, Zhang N, Chen C, Chen S, Xu J, Zhou Y, Zhao X, Cui Y (2019) Influence of the OATP polymorphism on the population pharmacokinetics of methotrexate in Chinese patients. Curr Drug Metab 20:592\u2013600. https:\/\/doi.org\/10.2174\/1389200220666190701094756","journal-title":"Curr Drug Metab"},{"key":"3579_CR63","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1002\/cncr.20152","volume":"100","author":"KR Crews","year":"2004","unstructured":"Crews KR, Liu T, Rodriguez-Galindo C, Tan M, Meyer WH, Panetta JC, Link MP, Daw NC (2004) High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer 100:1724\u20131733. https:\/\/doi.org\/10.1002\/cncr.20152","journal-title":"Cancer"},{"key":"3579_CR64","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1056\/NEJM199802193380803","volume":"338","author":"WE Evans","year":"1998","unstructured":"Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH (1998) Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338:499\u2013505. https:\/\/doi.org\/10.1056\/NEJM199802193380803. (PubMed: 9468466)","journal-title":"N Engl J Med"},{"key":"3579_CR65","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00467-008-0997-5","volume":"24","author":"MM Rhodin","year":"2009","unstructured":"Rhodin MM, Anderson BJ, Peters AM, Coulthard MG, Wilkins B, Cole M, Chatelut E, Grubb A, Veal GJ, Keir MJ, Holford NHG (2009) Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol 24:67\u201376. https:\/\/doi.org\/10.1007\/s00467-008-0997-5","journal-title":"Pediatr Nephrol"},{"key":"3579_CR66","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/mpo.2950240303","volume":"24","author":"MG Donelli","year":"1995","unstructured":"Donelli MG, Zucchetti M, Robatto A, Perlangeli V, D\u2019Incalci M, Masera G, Rossi MR (1995) Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia. Med Pediatr Oncol 24:154\u2013159. https:\/\/doi.org\/10.1002\/mpo.2950240303","journal-title":"Med Pediatr Oncol"},{"key":"3579_CR67","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1373\/clinchem.2007.099648","volume":"54","author":"F Ceriotti","year":"2008","unstructured":"Ceriotti F, Boyd JC, Klein G, Henny J, Queralt\u00f3 J, Kairisto V, Panteghini M, Committee IFCC, on Reference Intervals and Decision Limits (C-RIDL), (2008) Reference intervals for serum creatinine concentrations: assessment of available data for global application. Clin Chem 54:559\u2013566. https:\/\/doi.org\/10.1373\/clinchem.2007.099648","journal-title":"Clin Chem"},{"key":"3579_CR68","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.3899\/jrheum.131290","volume":"41","author":"E den Boer","year":"2014","unstructured":"den Boer E, de Rotte MC, Pluijm SM, Heil SG, Hazes JM, de Jonge R (2014) Determinants of erythrocyte methotrexate polyglutamate levels in rheumatoid arthritis. J Rheumatol 41:2167\u20132178. https:\/\/doi.org\/10.3899\/jrheum.131290","journal-title":"J Rheumatol"},{"key":"3579_CR69","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1002\/art.24653","volume":"60","author":"LK Stamp","year":"2009","unstructured":"Stamp LK, O\u2019Donnell JL, Chapman PT, Zhang M, Frampton C, James J, Barclay ML (2009) Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment. Arthritis Rheum 60:2248\u20132256. https:\/\/doi.org\/10.1002\/art.24653","journal-title":"Arthritis Rheum"},{"key":"3579_CR70","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/jcph.488","volume":"55","author":"F Foissac","year":"2015","unstructured":"Foissac F, Bouazza N, Valade E, De Sousa MM, Fauchet F, Benaboud S, Hirt D, Tr\u00e9luyer JM, Urien S (2015) Prediction of drug clearance in children. J Clin Pharmacol 55:739\u2013747. https:\/\/doi.org\/10.1002\/jcph.488","journal-title":"J Clin Pharmacol"},{"key":"3579_CR71","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","volume":"18","author":"HM Kantarjian","year":"2000","unstructured":"Kantarjian HM, O\u2019Brien S, Smith TL, Cortes J, Giles FJ, Beran M, Pierce S, Huh Y, Andreeff M, Koller C, Ha CS, Keating MJ, Murphy S, Freireich EJ (2000) Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 18:547\u2013561. https:\/\/doi.org\/10.1200\/JCO.2000.18.3.547","journal-title":"J Clin Oncol"},{"key":"3579_CR72","doi-asserted-by":"publisher","first-page":"5066","DOI":"10.1016\/S0021-9258(17)42956-5","volume":"259","author":"G Fabre","year":"1984","unstructured":"Fabre G, Fabre I, Matherly LH, Cano JP, Goldman ID (1984) Synthesis and properties of 7-hydroxymethotrexate polyglutamyl derivatives in Ehrlich ascites tumor cells in vitro. J Biol Chem 259:5066\u20135072. https:\/\/doi.org\/10.1016\/S0021-9258(17)42956-5","journal-title":"J Biol Chem"},{"key":"3579_CR73","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/cad.0b013e3282f21376","volume":"19","author":"C Dupuis","year":"2008","unstructured":"Dupuis C, Mercier C, Yang C, Monjanel-Mouterde S, Ciccolini J, Fanciullino R, Pourroy B, Deville JL, Duffaud F, Bagarry-Liegey D, Durand A, Iliadis A, Favre R (2008) High-dose methotrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategy. Anticancer Drugs 19:267\u2013273. https:\/\/doi.org\/10.1097\/cad.0b013e3282f21376","journal-title":"Anticancer Drugs"},{"key":"3579_CR74","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1200\/JCO.1994.12.8.1667","volume":"12","author":"MV Relling","year":"1994","unstructured":"Relling MV, Fairclough D, Ayers D, Crom WR, Rodman JH, Pui CH, Evans WE (1994) Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 12:1667\u20131672. https:\/\/doi.org\/10.1200\/JCO.1994.12.8.1667","journal-title":"J Clin Oncol"},{"key":"3579_CR75","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/BF00546719","volume":"26","author":"J Hendel","year":"1984","unstructured":"Hendel J, Nyfors A (1984) Nonlinear renal elimination kinetics of methotrexate due to saturation of renal tubular reabsorption. Eur J Clin Pharmacol 26:121\u2013124. https:\/\/doi.org\/10.1007\/BF00546719","journal-title":"Eur J Clin Pharmacol"},{"key":"3579_CR76","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1097\/FPC.0b013e328343dd93","volume":"21","author":"TS Mikkelsen","year":"2011","unstructured":"Mikkelsen TS, Thorn CF, Yang JJ, Ulrich CM, French D, Zaza G, Dunnenberger HM, Marsh S, McLeod HL, Giacomini K, Becker ML, Gaedigk R, Leeder JS, Kager L, Relling MV, Evans W, Klein TE, Altman RB (2011) PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics 21:679\u2013686. https:\/\/doi.org\/10.1097\/FPC.0b013e328343dd93","journal-title":"Pharmacogenet Genomics"},{"key":"3579_CR77","doi-asserted-by":"crossref","unstructured":"Borsi JD, Moe PJ (1987) A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 to 33.6 g\/m2 in children with acute lymphoblastic leukemia. Cancer 60:5\u201313","DOI":"10.1002\/1097-0142(19870701)60:1<5::AID-CNCR2820600103>3.0.CO;2-D"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03579-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-023-03579-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03579-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T07:03:19Z","timestamp":1704870199000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-023-03579-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,7]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["3579"],"URL":"https:\/\/doi.org\/10.1007\/s00228-023-03579-0","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,7]]},"assertion":[{"value":"4 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval is required\/exemption granted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}